Health and Human Services Secretary Alex Azar at the National Academy of Sciences last year. Photo: Alex Wong/Getty Images

More transparency about the cost of prescription drugs is unlikely to directly lower their price, experts say, poking a hole in a buzzy Washington talking point.

Why it matters: "Transparency" comes up often in discussions about how to lower drug prices. And though more information is undoubtedly important, something has to be done with that information to actually get costs down.

The big picture: We usually don't know how much insurance plans end up paying for most drugs, and we also don't know how much of a cut the system's middlemen keep for themselves. Transparency efforts often focus either on illuminating how money moves through the drug supply chain, or requiring drugmakers to justify hikes in their list prices.

  • This information may have a shaming effect, but drug companies would still be free to charge what they want. And consumers often have limited or no ability to choose a cheaper drug.
  • There are exceptions — like the new ban that on "gag clauses" that prevented patients from knowing when paying cash would be cheaper than using their insurance. But so far those circumstances have been relatively limited.

Yes, but: Transparency measures still matters, because “it’s hard to come up with really reasonable solutions if you’re really working in the dark," said Vanderbilt's Stacie Dusetzina.

  • It could help employers and insurance plans “understand where they could do a better job squeezing out some of this excess profit," she said, but ultimately "it’s necessary but not sufficient for reducing drug prices.”

Details: A handful of states have already passed laws requiring drug companies to report the rationale behind their price spikes, but most don't do anything to actually block or prevent those spikes.

  • Maryland passed penalties for "price gouging," but the law has been found unconstitutional. The state has asked the Supreme Court to hear the case.
  • A Health Affairs analysis of California's transparency law found that it is unlikely to have much of an impact on drug spending unless it's paired with additional incentives for consumers to use lower-priced drugs.

The bottom line: "Transparency can help the public and policy makers make more informed decisions about what to do about high drug prices - who to target, what policies to put in place, etc," said Walid Gellad, a professor at the University of Pittsburgh. "Just the transparency alone is unlikely to lower prices."

Go deeper

Updated 23 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 11:30 p.m. ET: 31,478,387 — Total deaths: 968,726 Total recoveries: 21,622,862Map.
  2. U.S.: Total confirmed cases as of 11:30 p.m. ET: 6,895,685 — Total deaths: 200,768 — Total recoveries: 2,646,959 — Total tests: 96,612,436Map.
  3. Health: The U.S. reaches 200,000 coronavirus deaths — The CDC's crumbling reputation — America turns against coronavirus vaccine.
  4. Politics: Elected officials are failing us on much-needed stimulus.
  5. Business: Two-thirds of business leaders think pandemic will lead to permanent changes — Fed chair warns economy will feel the weight of expired stimulus.
  6. Sports: NFL fines maskless coaches.

Trump pushes to expand ban against anti-racism training to federal contractors

Trump speaking at Moon Township, Penns., on Sept. 22. Photo: Mandel Ngan/AFP via Getty Images

President Trump announced late Tuesday that the White House attempt to halt federal agencies' anti-racism training would be expanded to block federal contractors from "promoting radical ideologies that divide Americans by race or sex."

Why it matters: The executive order appears to give the government the ability to cancel contracts if anti-racist or diversity trainings focused on sexual identity or gender are organized. The memo applies to executive departments and agencies, the U.S. military, federal contractors and federal grant recipients.

Dan Primack, author of Pro Rata
4 hours ago - Economy & Business

GoodRx prices IPO at $33 per share, valued at $12.7 billion

Illustration: Sarah Grillo/Axios

GoodRx, a price comparison app for prescription drugs at local pharmacies, on Tuesday night raised $1.14 billion in its IPO, Axios has learned.

By the numbers: GoodRx priced its shares at $33 a piece, above its $24-$28 per share offering range, which will give it an initial market cap of around $12.7 billion.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!